Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 3498Neoplasms 2739Prostatic Neoplasms 1583Colorectal Neoplasms 1247Lung Neoplasms 1188Motor Activity 766Head and Neck Neoplasms 621Pancreatic Neoplasms 601Colonic Neoplasms 586Uterine Cervical Neoplasms 567Carcinoma, Non-Small-Cell Lung 560Carcinoma, Hepatocellular 558Rectal Neoplasms 516Stomach Neoplasms 493Brain Neoplasms 436Anxiety Disorders 401Ovarian Neoplasms 399Pain 376Esophageal Neoplasms 347Neoplasm Metastasis 340Polycystic Ovary Syndrome 339Fatigue 324Urinary Bladder Neoplasms 314Precursor Cell Lymphoblastic Leukemia-Lymphoma 303Melanoma 298Depression 286Multiple Myeloma 283Endometrial Neoplasms 263Lymphoma 258Hematologic Neoplasms 251

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × OTHER × Hypereosinophilic Syndrome × Clear all
NCT00038675 2022-01-04

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

M.D. Anderson Cancer Center

Phase NA Completed
125 enrolled 9 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Polycythemia Vera, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡